jameela 30 0.15 mg - 0.03 mg filmomh. tabl.
aurobindo pharma b.v. - desogestrel 0,15 mg; ethinylestradiol 0,03 mg - filmomhulde tablet - 0,15 mg/0,03 mg - ethinylestradiol 0.03 mg; desogestrel 0.15 mg - desogestrel and ethinylestradiol
lavinia 0.1 mg - 0.02 mg filmomh. tabl.
theramex ireland ltd. - levonorgestrel 0,1 mg; ethinylestradiol 0,02 mg - filmomhulde tablet - 0,10 mg - 0,02 mg - ethinylestradiol 20 µg; levonorgestrel 100 µg - levonorgestrel and ethinylestradiol
levorichter 30 0.03 mg - 0.15 mg omh. tabl.
gedeon richter plc - ethinylestradiol 0,03 mg; levonorgestrel 0,15 mg - omhulde tablet - 0,030 mg - 0,150 mg - ethinylestradiol 30 µg; levonorgestrel 150 µg - levonorgestrel and ethinylestradiol
microgynon 20 0.1 mg/0.02 mg omh. tabl.
bayer sa-nv - ethinylestradiol 0,02 mg; levonorgestrel 0,1 mg - omhulde tablet - 0,100 mg - 0,020 mg - ethinylestradiol 20 µg; levonorgestrel 100 µg - levonorgestrel and ethinylestradiol
perynella 0.02 mg - 3 mg filmomh. tabl.
exeltis germany gmbh - ethinylestradiol 0,02 mg; drospirenon 3 mg - filmomhulde tablet - 0,02 mg - 3 mg - drospirenon 3 mg; ethinylestradiol 0.02 mg - drospirenone and ethinylestradiol
seasonique filmomh. tabl.
theramex ireland ltd. - levonorgestrel 0,15 mg (roze tablet); ethinylestradiol 0,03 mg (roze tablet); ethinylestradiol 0,01 mg (witte tablet) - filmomhulde tablet - levonorgestrel 0.15 mg; ethinylestradiol 0.03 mg; ethinylestradiol 0.01 mg - levonorgestrel and ethinylestradiol
mhyosphere pcv id
laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - varkens - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.
adrenaline sterop 0.5 mg/1 ml inj. opl. i.v./i.m. amp.
laboratoires sterop sa-nv - epinefrine 0,5 mg/ml - oplossing voor injectie - 0,5 mg/1 ml - epinefrine 0.5 mg/ml - epinephrine
adrenaline sterop 1 mg/1 ml inj. opl. i.v./i.m. amp.
laboratoires sterop sa-nv - epinefrine 1 mg/ml - oplossing voor injectie - 1 mg/1 ml - epinefrine 1 mg/ml - epinephrine
leflunomide ab 10 mg filmomh. tabl.
aurobindo sa-nv - leflunomide 10 mg - filmomhulde tablet - leflunomide